Virax Biolabs Group Limited

VRAX

KYG9495L1251

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 16/06/2026 BST			5-day change	1st Jan Change
0.1570 ^USD	-9.20%		-16.58%	-54.60%

05-26	Virax Biolabs Group Limited Reports Positive Early Clinical Data for Viraximmune in Long Covid and Related Post-Acute Infection Syndromes	CI
03-18	Virax Biolabs Group Limited Approves Fourth Amended and Restated Memorandum and Articles of Association	CI

Virax Biolabs Closes $5 Million Direct Offering of Shares

Published on 08/23/2024 at 09:29 pm BST - Modified on 08/23/2024 at 09:54 pm BST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Virax Biolabs Group Limited

05-26	Virax Biolabs Group Limited Reports Positive Early Clinical Data for Viraximmune in Long Covid and Related Post-Acute Infection Syndromes	CI
03-18	Virax Biolabs Group Limited Approves Fourth Amended and Restated Memorandum and Articles of Association	CI
12-03	Virax Biolabs Group Limited announced that it has received $4.99875 million in funding	CI
12-02	Virax Biolabs Group Limited announced that it expects to receive $4.99875 million in funding	CI
12-02	Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2025	CI
11-03	Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive Fda Feedback for Viraximmune?? Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes	CI
26/08/25	Virax Biolabs to Collaborate With Emory University on Long COVID Clinical Studies	MT
26/08/25	Virax Biolabs partners with Emory University on ViraxImmune(TM) clinical studies	RE
26/08/25	Virax Biolabs Group Limited Partners with Emory University on ViraxImmune Clinical Studies	CI
29/07/25	Virax Biolabs Group Limited Announces Board Changes	CI
29/07/25	Virax Biolabs Group appoints Iain Miller, Ph.D. as independent director to accelerate commercial strategy	RE
18/07/25	Virax Biolabs Gets Nasdaq Non-Compliance Notice	MT
02/07/25	Virax Biolabs Group Limited Reports Earnings Results for the Full Year Ended March 31, 2025	CI
13/06/25	Virax Biolabs Group CFO Jason Davis To Resign	RE
31/03/25	HC Wainwright Initiates Virax Biolabs at Buy With $3 Price Target	MT

Chart Virax Biolabs Group Limited

Duration

Period

VRAX: Dynamic Chart

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individualâ€™s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).

Employees

Sector

Biotechnology & Medical Research

More about the company